Abstract
A growing body of evidence suggests that omega (ω)-3 polyunsaturated fatty acids (PUFAs) are clinically useful in patients with psychiatric disorders. In the present review, we summarize the findings of randomized, placebocontrolled clinical trials that have focused on the potential therapeutic utility of ω-3 PUFAs in patients with mental illnesses. We searched the PubMed database for placebo-controlled clinical trials using the keywords “PUFAs”, “omega-3”, “eicosapentaenoic acid”, and “docosahexaenoic acid” in combination with the following terms: “anxiety disorders”, “mood disorders”, “autism”, “attention-deficit hyperactivity disorder” (ADHD), “personality disorders”, and “schizophrenia”. The literature review indicated that personality disorders, autism, and anxiety disorders have been investigated less frequently than mood disorders, schizophrenia, and ADHD. Although no definite conclusions can be drawn on the therapeutic efficacy of ω-3 PUFAs in the majority of the psychiatric illnesses examined here, the evidence suggests that these molecules have a potential preventive role in people at extremely high risk for developing psychosis. Future studies in the field should examine ω-PUFAs turnover in neural membranes. Moreover, special attention should be paid to potential confounds, such as smoking and dietary habits.
Keywords: Docosahexaenoic acid, eicosapentaenoic acid, omega-3, psychiatric disorders, trials.
Current Drug Discovery Technologies
Title:Randomized Placebo-Controlled Trials of Omega-3 Polyunsaturated Fatty Acids in Psychiatric Disorders: A Review of the Current Literature
Volume: 10 Issue: 3
Author(s): Pierluigi Politi, Matteo Rocchetti, Enzo Emanuele, Mariangela Rondanelli and Francesco Barale
Affiliation:
Keywords: Docosahexaenoic acid, eicosapentaenoic acid, omega-3, psychiatric disorders, trials.
Abstract: A growing body of evidence suggests that omega (ω)-3 polyunsaturated fatty acids (PUFAs) are clinically useful in patients with psychiatric disorders. In the present review, we summarize the findings of randomized, placebocontrolled clinical trials that have focused on the potential therapeutic utility of ω-3 PUFAs in patients with mental illnesses. We searched the PubMed database for placebo-controlled clinical trials using the keywords “PUFAs”, “omega-3”, “eicosapentaenoic acid”, and “docosahexaenoic acid” in combination with the following terms: “anxiety disorders”, “mood disorders”, “autism”, “attention-deficit hyperactivity disorder” (ADHD), “personality disorders”, and “schizophrenia”. The literature review indicated that personality disorders, autism, and anxiety disorders have been investigated less frequently than mood disorders, schizophrenia, and ADHD. Although no definite conclusions can be drawn on the therapeutic efficacy of ω-3 PUFAs in the majority of the psychiatric illnesses examined here, the evidence suggests that these molecules have a potential preventive role in people at extremely high risk for developing psychosis. Future studies in the field should examine ω-PUFAs turnover in neural membranes. Moreover, special attention should be paid to potential confounds, such as smoking and dietary habits.
Export Options
About this article
Cite this article as:
Politi Pierluigi, Rocchetti Matteo, Emanuele Enzo, Rondanelli Mariangela and Barale Francesco, Randomized Placebo-Controlled Trials of Omega-3 Polyunsaturated Fatty Acids in Psychiatric Disorders: A Review of the Current Literature, Current Drug Discovery Technologies 2013; 10 (3) . https://dx.doi.org/10.2174/1570163811310030007
DOI https://dx.doi.org/10.2174/1570163811310030007 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Organoselenium Compounds as Potential Neuroprotective Therapeutic Agents
Current Organic Chemistry Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Involvement of the Endocannabinoid System in Motor Disorders
Current Medicinal Chemistry - Central Nervous System Agents Endocannabinoid Metabolic Pathways and Enzymes
Current Drug Targets - CNS & Neurological Disorders A Critical Review of Rating Scales in the Assessment of Movement Disorders in Schizophrenia
Current Drug Targets Recent Developments in Studies of l-Stepholidine and its Analogs: Chemistry, Pharmacology and Clinical Implications
Current Medicinal Chemistry Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review
Current Neuropharmacology Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Effects of Adding Large Doses of Arachidonic Acid to Docosahexaenoic Acid on Social Impairment in Individuals with Autism Spectrum Disorders
Current Psychopharmacology Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?
Current Molecular Pharmacology Aripiprazole in Children and Adolescents with Schizophrenia
Current Psychopharmacology Translating Genetic Findings into Therapy in Parkinson Disease
Recent Patents on CNS Drug Discovery (Discontinued) Tremor and Rigidity in Patients with Parkinson’s Disease: Emphasis on Epidemiology, Pathophysiology and Contributing Factors
CNS & Neurological Disorders - Drug Targets Improving Adherence to Antipsychotic Pharmacotherapy
Current Clinical Pharmacology Homology Modeling of Adenosine A2A Receptor and Molecular Docking for Exploration of Appropriate Potent Antagonists for Treatment of Parkinsons Disease
Current Aging Science Clinical Management of Arrhythmogenic Right Ventricular Cardiomyopathy: An Update
Current Pharmaceutical Design The Role of Topiramate in the Management of Cocaine Addiction: a Possible Therapeutic Option
Current Neuropharmacology Double-Faced Role of Human Mesenchymal Stem Cells and their Role/Challenges in Cancer Therapy
Current Stem Cell Research & Therapy Attention Deficit and Hyperactivity Disorder: Controversies of Diagnosis and Safety of Pharmacological and Nonpharmacological Treatment
Current Drug Safety